Biology:Adegramotide
From HandWiki
Short description: Experimental cancer drug
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C87H123N19O24 |
Molar mass | 1819.050 g·mol−1 |
3D model (JSmol) | |
| |
|
Adegramotide (DSP-7888) is an experimental drug intended for treatment of glioblastoma multiforme.[1] It is a peptide vaccine and, as of 2017, in phase II clinical trials.[2][3]
References
- ↑ "Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies". Targeted Oncology 16 (4): 461–469. July 2021. doi:10.1007/s11523-021-00813-6. PMID 33939067.
- ↑ Boston Biomedical (11 May 2017). A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy. U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT03149003.
- ↑ "Adegrapepimut-S" (in en). https://pubchem.ncbi.nlm.nih.gov/compound/121488164.
Original source: https://en.wikipedia.org/wiki/Adegramotide.
Read more |